NEW YORK (GenomeWeb) – Illumina has registered its MiSeqDx instrument for clinical use in Australia, the company said today. The Australian Therapeutic Goods Administration has listed the instrument in the Australian Register of Therapeutic Goods as a cleared in vitro diagnostic medical device, Illumina said.

"This is an exciting milestone for Illumina and for our clinical customers in Australia," Tim Orpin, vice president and general manager for Illumina in the Asia Pacific region, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.